20.02

1.86% 0.365

After Hours: 19.80 -0.215 -1.07%

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $20.02, with a volume of 693.60K. It is up +1.86% in the last 24 hours and up +7.38% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Previous Close:

$19.65

Open:

$20.01

24h Volume:

693.60K

Relative Volume:

0.82

Market Cap:

$1.52B

Revenue:

$80.89M

Net Income/Loss:

$-144.73M

P/E Ratio:

-7.5244

EPS:

-2.66

Net Cash Flow:

$-83.87M

1W Performance:

+0.28%

1M Performance:

+7.38%

6M Performance:

-3.64%

1Y Performance:

+150.50%

1-Day Range:

$19.24

$20.41

1-Week Range:

$19.17

$20.66

52-Week Range:

$7.79

$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

(415) 660-5320

Address

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Employee

284

Twitter

Next Earnings Date

2024-10-14

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	20.02	1.52B	80.89M	-144.73M	-83.87M	-2.66
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

01:14 AM

Royal Bank of Canada Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $27.00 - MarketBeat

01:14 AM

04:48 AM

Nurix Therapeutics' SWOT analysis: protein degrader stock's potential By Investing.com - Investing.com Australia

04:48 AM

01:02 AM

Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory Shift - TipRanks

01:02 AM

Jan 29, 2025

Nurix Therapeutics Reports Solid Progress and Strong Pipeline - TipRanks

Jan 29, 2025

Nurix Therapeutics' SWOT analysis: protein degrader stock's potential - Investing.com India

Jan 29, 2025

Stifel raises Nurix stock price target to $36, maintains Buy - MSN

Jan 29, 2025

JPMorgan Chase & Co. Has Lowered Expectations for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat

Jan 29, 2025

HC Wainwright Increases Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00 - MarketBeat

Jan 29, 2025

Needham & Company LLC Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat

Jan 29, 2025

Nurix Therapeutics (NASDAQ:NRIX) Given New $36.00 Price Target at Stifel Nicolaus - MarketBeat

Jan 29, 2025

8 Analysts Have This To Say About Nurix Therapeutics - Benzinga

Jan 29, 2025

Jan 28, 2025

Nurix Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended November 30, 2024 - Marketscreener.com

Jan 28, 2025